Department of Oncology, University of Alberta, Edmonton, Alberta, T6G 1Z2, Canada.
Trends Mol Med. 2010 Jul;16(7):329-35. doi: 10.1016/j.molmed.2010.05.001. Epub 2010 Jun 3.
The TSC1/TSC2 tumor-suppressor complex regulates cell growth via controlling the mTOR (mammalian target of rapamycin) signaling pathway, which contributes to several disease processes, including cancer and diabetes. Abnormal activation of mTOR uncouples anabolic cell growth processes such as protein and lipid synthesis from external growth factor or nutrient cues. However, abnormal activation of mTOR upon loss of TSC1/TSC2 complex function is now known to lead to compensatory mechanisms that restrict the development of malignant tumors. The rare occurrence of complete loss of TSC1/TSC2 function in human tumors suggests that retaining growth suppressor activity might be beneficial during tumour evolution, perhaps by promoting survival when cells grow in a nutrient-limited environment.
TSC1/TSC2 肿瘤抑制复合物通过控制 mTOR(雷帕霉素的哺乳动物靶标)信号通路来调节细胞生长,该信号通路参与了多种疾病过程,包括癌症和糖尿病。mTOR 的异常激活会使细胞生长过程(如蛋白质和脂质合成)与外部生长因子或营养线索脱耦联。然而,现在已知 TSC1/TSC2 复合物功能丧失时 mTOR 的异常激活会导致限制恶性肿瘤发展的代偿机制。在人类肿瘤中 TSC1/TSC2 功能完全丧失的情况很少见,这表明在肿瘤进化过程中保留生长抑制活性可能是有益的,当细胞在营养有限的环境中生长时,这种活性可能有助于促进细胞存活。